Literature DB >> 15477876

Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.

L Zeng1, N Kyprianou.   

Abstract

Early diagnosis of prostate cancer holds tremendous promise for the effective therapy and impact on survival of prostate cancer patients. High-grade prostatic intraepithelial neoplasia (HGPIN) is generally accepted as a lesion indicative of a late pathological event in the premalignant changes leading to full development of prostate cancer. This review seeks to identify specific molecular events that may be linked directly to the molecular transition from benign prostate epithelial cells to prostate carcinoma. HGPIN is pathologically detected in a limited group of men undergoing prostate cancer screening for an elevated serum prostate-specific antigen (PSA) or abnormal digital rectal examination (DRE). Loss of apoptotic control provides a molecular basis for the contribution of specific defective steps in the pathway towards development and progression of prostate cancer. Comparative dissection of the apoptosis status and expression profile of key apoptotic regulators among foci of highly proliferative benign prostatic epithelium, PIN and prostate adenocarcinoma from adjacent areas of the same gland revealed a novel insight into the dysfunctional apoptosis events contributing to prostate carcinogenesis. The sequential and notable loss of the three critical signaling components of the apoptotic action of transforming growth factor-beta (TGF-beta), in the prostate, that is, the transmembrane receptor II (TbetaRII), the key cell cycle inhibitor p27(Kip1), as well as the protagonist downstream effector of the TGF-beta signaling mechanism, Smad4, points to their potential value to 'faithfully' characterize HGPIN, as a premalignant prostate lesion. Recent evidence on the molecular changes in apoptosis regulators contributing to HGPIN and their role as molecular markers of disease onset, as well as candidates for therapeutic targeting/chemoprevention of prostate cancer in its early stages will be discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15477876     DOI: 10.1038/sj.pcan.4500757

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  6 in total

1.  Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract.

Authors:  Gretchen E Garcia; Arevalo Nicole; Shylesh Bhaskaran; Ashima Gupta; Natasha Kyprianou; Addanki P Kumar
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

2.  Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer.

Authors:  E M Schaeffer; L Marchionni; Z Huang; B Simons; A Blackman; W Yu; G Parmigiani; D M Berman
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

3.  MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.

Authors:  Raj R Bhanvadia; Calvin VanOpstall; Hannah Brechka; Nimrod S Barashi; Marc Gillard; Erin M McAuley; Juan Manuel Vasquez; Gladell Paner; Wen-Ching Chan; Jorge Andrade; Angelo M De Marzo; Misop Han; Russell Z Szmulewitz; Donald J Vander Griend
Journal:  Clin Cancer Res       Date:  2018-05-01       Impact factor: 12.531

4.  XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells.

Authors:  Zhaoquan Xing; Zunlin Zhou; Rong Yu; Shuling Li; Chunde Li; Sten Nilsson; Zhaoxu Liu
Journal:  J Exp Clin Cancer Res       Date:  2010-12-11

5.  Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer.

Authors:  Vijayalakshmi Ananthanarayanan; Ryan J Deaton; Ximing J Yang; Michael R Pins; Peter H Gann
Journal:  BMC Cancer       Date:  2006-03-17       Impact factor: 4.430

6.  5α-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores.

Authors:  Alexander B Opoku-Acheampong; Jamie N Henningson; Amanda P Beck; Brian L Lindshield
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.